Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.78+0.03 (+1.71%)
Close on Nov 17, 2026Market cap $792.02MP/E –Yield –
Lexicon Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Lexicon Pharmaceuticals's price to sales ratio was 20.2× on Nov 11, 2026, against 7.4× a year earlier. Over the last 5 years it ranged from 0.4× to 457.3×, with a median of 13.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 20.2× | +14.2 |
| 2025 | Dec 31, 2025 | 5.9× | −35.1 |
| 2024 | Dec 31, 2024 | 41.1× | −372.0 |
| 2023 | Nov 30, 2023 | 413.1× | +314.7 |
| 2021 | Oct 29, 2021 | 98.4× | +86.9 |
| 2020 | Dec 31, 2020 | 11.5× | +10.1 |
| 2019 | Dec 31, 2019 | 1.4× | −7.4 |
| 2018 | Dec 31, 2018 | 8.8× | −4.1 |
| 2017 | Dec 29, 2017 | 12.8× | +5.0 |
| 2016 | Dec 30, 2016 | 7.9× | −46.5 |
| 2015 | Dec 31, 2015 | 54.4× | −113.8 |
| 2014 | Dec 31, 2014 | 168.2× | −217.2 |
| 2012 | May 31, 2012 | 385.4× | – |
See a number that looks wrong?